Kornimate/medical-research-clean huggingface dataset:
magnetic resonance imaging and spectroscopy of the prostate

Conditions: Prostate Cancer

Summary: past studies have shown that mri is useful for staging prostate cancer. this study will use magnetic resonance spectroscopic imaging (mrsi) to obtain more information. mrsis with mris help doctors locate prostate cancer and determine the extent of tumor before deciding on treatment. this study looks at structural and chemical properties of prostates in prostate cancer patients before and after treatment.


Eligibility criteria:
inclusion criteria: * prostate cancer patients willing to undergo a mri and mrsi exam exclusion criteria: * patients with prostate cancer and bone or lymph node metastasis * patients who can not have an mri exam

Keywords: mrsi mri prostate cancer
health literacy and overweight in adolescents

Conditions: Overweight and Obesity

Summary: obesity in children and adolescents has become a major public health problem in recent years. in belgium, 20% of people aged between 2 and 17 are overweight and 7% suffer from obesity. while studies often associate this overweight with socio-economic level, other factors, such as health literacy (hl), may also play a role. among adolescents, some studies have shown an association between the level of hl and the body mass index (bmi). our study aims to investigate the association between hl of adolescents and their bmi. this is a cross-sectional survey among 9 high schools in a medium city of belgium, including 254 high school students aged between 12-17 years. health literacy was assessed by the health literacy measure for adolescents (helma). student's age, sex, weight, size and parental socio-economic status are gathered in the medical file during the medical examination organized by the schools after obtaining the informed consent of the students and their parents.


Eligibility criteria:
inclusion criteria: * studying in one of the participating school * being in 2nd or 4th year * parental consent to participate exclusion criteria: * none
a randomized phase iii clinical trial of daunoxome versus combination chemotherapy with adriamycin/bleomycin/vincristine (abv) in the treatment of hiv-associated kaposi's sarcoma.

Conditions: Sarcoma, Kaposi; HIV Infections

Summary: to compare the toxicity profiles (severity and time to onset from initiation of therapy) between daunorubicin (liposomal) and combination chemotherapy with doxorubicin/bleomycin/vincristine (abv), with both regimens administered in combination with antiretroviral therapy. to compare the duration of responses, response rates, and times to response.


Eligibility criteria:
inclusion criteria patients must have: * hiv infection. * advanced kaposi's sarcoma. prior medication: allowed: * prior intralesional vinblastine. exclusion criteria co-existing condition: patients with the following symptoms and conditions are excluded: * acute intercurrent infection other than genital herpes. * uncompensated cardiovascular, hepatic, renal, or pulmonary disease unrelated to kaposi's sarcoma. * symptomatic peripheral neuropathy. * any condition that compromises ability to give informed consent or complete the study. concurrent medication: excluded: * concurrent ganciclovir. patients with the following prior conditions are excluded: * symptomatic aids-defining opportunistic infection within 2 weeks of entry. * history of malignancy other than kaposi's sarcoma, basal cell carcinoma, or carcinoma in situ of the cervix. prior medication: excluded: * prior systemic chemotherapy. * intralesional therapies within 7 days prior to study entry. * growth factors (g-csf or gm-csf), immune modifiers, or investigational agents within 14 days prior to study entry. * interferon preparations (alpha or beta) within 28 days prior to study entry. prior treatment: excluded within 7 days prior to study entry: * radiation. * local therapies (e.g., cryotherapy).

Keywords: vincristine sarcoma, kaposi liposomes doxorubicin acquired immunodeficiency syndrome bleomycin daunorubicin drug carriers
incidence and outcomes of acute kidney injury in trauma patients admitted to critical care

Conditions: Acute Kidney Injury; Trauma; Complications

Summary: acute kidney injury (aki) is a common complication that increases lenght of stay and mortality in trauma patients admitted to the intensive care unit (icu). the aim of this study is to identify the incidence and outcomes of trauma patients, defined by kidney disease improving global outcomes (kdigo) criteria, at single center level 3 icu.

trauma can cause high mortality and morbidity by affecting different organ systems. acute kidney injury (aki) is a common complication in trauma patients admitted to the intensive care unit (icu). direct kidney injury, hypotension, hypoperfusion, rhabdomyolysis, abdominal compartment syndrome, sepsis and critical care medications are possible causes of aki in trauma patients. the incidence of aki can be up to 10%, and mortality rate up to 60-80% in trauma patients. since aki is not only a rare complication but also a risk factor for mortality in critically ill trauma patients, it is essential to establish a strategy to prevent aki and related complications, to determine the incidence and risk factors of aki, and to improve patients outcomes. survivors of aki may have variable recovery of kidney function and might prone to late morbidity and mortality. in this study incidence of aki was defined using the kdigo criteria according to the change of serum creatine levels. 171 all type of trauma patients admitted to level 3 icu, from january 2014 to december 2018 included the retrospectve observational study. demographic data, type of injury, rates of complications, risk factors for aki, mortality, lenght of stay (los) in icu were evaluated. acute physiology and chronic health evaluation (apache ii and iv) score, simplified acute physiology score (saps ii and iii), glasgow coma scale (gcs), injury severity score (iss) and, trauma injury severity score (triss) were calculated on the day of admission. aki was defined using the kdigo criteria according to the serum creatinine. the spss 11.5 program was used for statistical analysis.

Eligibility criteria:
inclusion criteria: * all type of trauma patients admitted to level 3 icu, from january 2014 to december 2018 exclusion criteria: -

Keywords: trauma acute kidney injury intensive care unit
step: social support to empower parents

Conditions: Type 1 Diabetes

Summary: this rct intervention provides parental social support (informational, affirmational, and emotional) using parent mentors (experienced in the management of the chronic illness) for mothers and fathers of young children newly diagnosed with type 1 diabetes. the parent mentors provide both home visits and phone call support over the course of the first year after diagnosis. the hypothesis is that newly diagnosed parents who receive the intervention will perceive less parental concern and worry, less negative impact on the family, more perceived confidence and social support compared to those mothers and fathers not receiving the intervention.


Eligibility criteria:
inclusion criteria: * mothers and fathers of children 12 years and younger with type 1 diabetes
multiple micronutrients supplementation on angiogenesis and vasculogenesis factors, and fetal biometry

Conditions: Angiogenesis; Fetal Weight; Pregnancy Related; Nutrient Element Deficiency; High Risk Pregnancy

Summary: multiple micronutrients play an important role during pregnancy, since the decidualization and implantation phases. it has an impact on placentation and remodeling of blood vessels. the optimal early pregnancy conditions accompanied by great angiogenesis and vasculogenesis factors will influence fetal growth. this study aims to determine the effect of maternal multiple micronutrient supplementation on angiogenesis factors, vasculogenesis factors, and fetal biometry. it is a clustered randomized controlled trial that aims to determine the impact of maternal micronutrient supplementation on plgf levels, sflt-1/plgf ratio, mean pulsatility index of uterine artery, and fetal biometry (head circumference, femur length, and estimated fetal weight percentile). the target population for the study was all pregnant women who underwent antenatal check-ups at community health centers in dki jakarta.


Eligibility criteria:
inclusion criteria: 1. pregnant women with gestation age 8 - 14 weeks. 2. singleton pregnancy. 3. living in dki jakarta. 4. can consume tablets or caplets. 5. willing to only consume the vitamins used in the research 6. willing to undergo antenatal examination at community health centers in dki jakarta. 7. willing to be a research subject by signing the research consent form. exclusion criteria: 1. multiple pregnancies. 2. pregnancy with assisted reproduction. 3. history of polycystic ovary syndrome. 4. history of chronic hypertension. 5. history of gestational diabetes mellitus. 6. diagnosed with type 2 diabetes mellitus. 7. history of preeclampsia. 8. recurrent miscarriage (recurrent pregnancy loss). 9. maternal medical conditions (autoimmune; heart disease; malignancy). 10. history of chronic infection. 11. cannot consume tablets or caplets 12. planning to move out of dki jakarta before and/or not giving birth in dki jakarta.

Keywords: micronutrients angiogenesis vasculogenesis fetal biometry
improving activity and quality of life following orthopaedic trauma: the trauma collaborative care study (tccs)

Conditions: Severe Orthopedic Trauma

Summary: the study uses a multi-site, cluster design to determine the effectiveness of an intervention based on a trauma collaborative care (tcc) model in improving patient outcomes for persons with severe orthopedic trauma and enhancing both patient and provider satisfaction with overall care. the study will also determine the cost and cost-effectiveness of the intervention. primary hypothesis: compared to standard treatment alone, access to the tcc program plus standard treatment will result in lower rates of the composite outcome (i.e. positive for poor function, depression, and/or ptsd). secondary hypotheses: compared to standard treatment alone, access to the tcc program plus standard treatment will result in lower levels of pain and higher rates of return to usual major activity and higher levels of health related quality of life. in addition, both primary and secondary outcomes will correlate strongly with the intermediate outcome of self-efficacy.


Eligibility criteria:
inclusion criteria: 1. patients treated surgically for one or more orthopaedic injuries with initial admission to the trauma service of the participating hospital 2. ages 18-60 yrs inclusive 3. length of stay (los) \>=5 days or \>= 3 days with planned readmission for additional procedures 4. at least one orthopaedic injury of ais 3 or greater (determination based on information available at the time of enrollment) resulting from a moderate to high energy force (e.g. motor vehicle or motorcycle crash, high fall). injuries can include those to the upper or lower extremities, pelvis/acetabulum or spine. 5. traumatic amputations of the upper or lower extremities (excluding amputations to fingers or toes) exclusion criteria: 1. initial admission to non-trauma service. 2. peri-prosthetic fractures of the femur, regardless of etiology 3. patient eligible for the metrc outlet study, i.e. patient with: 1. gustilo type iii distal tibia and/or foot or type iii b or c ankle fractures with fracture pattern consistent with one of ota codes: 43b1.3, 43b2-b3, 43c, 44b, 44c, 81b2-b3, 82b, and 82c; 2. open or closed industrial foot crush injuries; 3. open or closed foot blast injuries. 4. patient requiring a legally authorized representative (as defined by an inability to answer the "evaluation of give consent" questions) 5. patient non-ambulatory due to an associated spinal cord injury 6. patient non-ambulatory pre-injury 7. non-english speaking 8. patient diagnosed with a severe psychosis 9. patient lives outside the hospital's catchment area and/or follow-up is planned at another medical center 10. severe problems with maintaining follow-up expected (e.g. patients who are prisoners or homeless at the time of injury or those who are severely intellectually challenged).
serotype distribution in hospitalized adult with pneumococcal community acquired pneumonia in france

Conditions: Pneumonia; Pneumococcal Infections; Community-acquired Pneumonia

Summary: cap'hospi is an observational, multicentric study in france which primary objective is to describe the proportion of community acquired pneumonia due to serotypes included in pcv20 among adults hospitalized for cap


Eligibility criteria:
inclusion criteria: 1. adults 18 years of age or older 2. admission to hospital for at least 24 hours 3. suspicion of community-acquired pneumonia at admission defined as the association of: radiologic findings consistent with pneumonia (eg, pleural effusion, increased pulmonary density due to infection and/or alveolar infiltrates \[multilobar, lobar, or segmental\] containing air bronchograms), and the presence of ≥2 of the following signs or symptoms: fever (oral temperature \>38°c or tympanic temperature \>38.5°c) in the 24 hours preceding admission; hypothermia (\ 20/min) ; malaise ; abnormal auscultatory findings suggestive of pneumonia (rales or evidence of pulmonary consolidation) 4. written informed consent from the patient exclusion criteria: 1. suspicion of tuberculosis 2. individuals placed under judicial protection 3. individuals who refuse the transfer of biological samples to the usa 4. patient developing signs and symptoms of pneumonia after having been hospitalized for 48 hours or more 5. pregnancy

Keywords: france vaccine pneumococcal infections
efficacy and safety of dexlansoprazole mr and lansoprazole on healing of erosive esophagitis

Conditions: Esophagitis, Reflux; Esophagitis, Peptic

Summary: the purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (qd) treatment with dexlansoprazole modified release (mr) 60 mg or 90 mg or lansoprazole 30 mg in healing subjects with endoscopically proven erosive esophagitis.

this is a phase 3, randomized, double-blind, multi-center, active-controlled, 3-arm study with an 8-week treatment period. this study will compare the efficacy of dexlansoprazole mr (60 mg qd and 90 mg qd) with that of lansoprazole (30 mg) when administered orally as a single daily dose in the morning, before breakfast. the study is designed to evaluate healing of erosive esophagitis and the effect of the therapy on relieving gastroesophageal reflux disease-related symptoms. the study consists of two periods, a screening period (maximum 21 days) and a treatment period, which will last 8 weeks.

Eligibility criteria:
inclusion criteria: * subject must have endoscopically confirmed erosive esophagitis as defined by the los angeles (la) classification grading system (a-d) exclusion criteria: * subject has a positive campylobacter-like organisms (clo) test for helicobacter (h.) pylori. * use of prescription or non-prescription proton pump inhibitors (ppis), histamine (h2) receptor antagonists or sucralfate, drugs with significant anticholinergic effects, misoprostol or prokinetics * use of antacids \[except for study supplied gelusil®\] * need for continuous anticoagulant therapy (blood thinners) * endoscopic barrett's esophagus and/or definite dysplastic changes in the esophagus * history of dilatation of esophageal strictures, other than schatzki's ring (a ring of mucosal tissue near the lower esophageal sphincter) * current or historical evidence of zollinger-ellison syndrome or other hypersecretory condition. * history of gastric, duodenal or esophageal surgery except simple oversew of an ulcer. * acute upper gastrointestinal hemorrhage within 4 weeks of the screening endoscopy

Keywords: erosive esophagitis
efficacy of levodopa/benserazide dispersible tablet on response fluctuations in pd patients with delayed on

Conditions: Parkinson Disease

Summary: the purpose of this study is to determine whether levodopa/benserazide dispersible is effective in the adjunctive treatment of parkinson's disease (pd) patients with delayed on.

delayed on is one of the motor complications of advanced pd patients that effect of anti-parkinsonian medication is delayed more than 40 minutes after intake. in the most severe cases, the effect does not appear even until next medication schedule, so called "no on" status. it is important to manage delayed on properly because it can interfere motor functions and quality of life of pd patients. levodopa/benserazide dispersible can be absorbed rapidly in the intestine, so theoretically it can break the poor response to conventional treatment of pd patients with delayed on. however, this has not been proven by clinical trials till now.

Eligibility criteria:
inclusion criteria: * male or female patients between 31 and 80 years * parkinson disease (pd) was diagnosed by united kingdom parkinson disease brain bank criteria * patients receiving stable levodopa treatment at least 2 weeks prior to baseline visit * delayed on was confirmed by a specialized pd diary that records change in motor symptoms 90 minute after the first morning dose. delayed on is defined as delay of more than 40 minutes after the first morning dose for resolution of off state or experience of no on state at least 1 per week. exclusion criteria: * existence of cognitive decline hard to participate in the clinical trial or k-minimental status exam score 24 or less * any contraindication of blood sampling * subjects with clinically significant psychiatric illness * subjects with a cancer or severe medical illness * lactating, pregnant, or possible pregnant * history of malignant melanoma * subjects with narrow-angle glaucoma * subjects with hypersensitivity to levodopa or benserazide * subjects treated with non-selective monoamine oxidase (mao)-b inhibitors * subjects with peptic ulcer, colitis, or gastrointestinal disease
description of joint population and assessment of impact on health status of orencia in patients with rheumatoid arthritis in france. a database analysis based on sfr's ora long-term cohort study

Conditions: Rheumatoid Arthritis

Summary: database analysis: * to describe how orencia is prescribed in france in rheumatoid arthritis (ra) * to describe joint population of orencia * to assess the impact of the treatment on health status of the treated population as assessed by morbid-mortality criteria * to describe therapeutic strategies and use of health services

* observational model: historic cohort generated from société française de rhumatologie's (sfr) orencia and rheumatoid arthritis (ora) registry * sampling method: all physicians and sites taking in charge ra patients received an invitation mailing to participate to ora * minimum age: 18 years old at orencia initiation

Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com. inclusion criteria: * adult outpatients, male or female aged ≥ 18 years old * diagnosed with a rheumatoid arthritis according to acr criteria * treated with orencia according to usual practice conditions from june 1st 2007 * agreeing to participate exclusion criteria: * patients treated by orencia in the context of clinical trials
artificial intelligence in colonoscopy

Conditions: Quality Indicators, Health Care; Artificial Intelligence (AI); Colonoscopy Diagnostic Techniques and Procedures

Summary: colorectal cancer is the second most common malignancy in the countries of the european union. colonoscopy is the primary method for detecting and preventing the development of colorectal cancer is endoscopic examination. this study aims to evaluate the impact of artificial intelligence on the detection rate of polyps and early stages of colorectal cancer.

colorectal cancer is the second most common malignancy in the countries of the european union. the primary method for detecting and preventing the development of colorectal cancer is endoscopic examination-colonoscopy, during which precancerous lesions such as adenomas and serrated polyps can be removed. the effectiveness of colonoscopy depends on the adenoma detection rate, which varies among endoscopists and is influenced by their skills and experience. it has been proven that high-quality colonoscopy prevents the omission of colorectal cancer, which might develop in the future as so-called interval cancer. a breakthrough in machine learning in recent years has enabled the development of commercial artificial intelligence systems. these systems aim to improve the detection rates of precancerous polyps and, consequently, potentially reduce the risk of developing colorectal cancer. artificial intelligence is also expected to help standardize performance across endoscopic procedures of varying quality, thereby contributing to a reduction in colorectal cancer incidence in the future. this study aims to evaluate the impact of artificial intelligence on the detection rate of polyps and early stages of colorectal cancer.

Eligibility criteria:
inclusion criteria: * consent to participate in the study, * age between 50 and 65 years, * scheduled outpatient colonoscopy. exclusion criteria: * previous colonoscopy, * history of colorectal surgery, * ongoing biological therapy for any indication, * primary sclerosing cholangitis, * familial polyposis syndrome, * chronic diarrhea, * ulcerative colitis, * crohn's disease.

Keywords: quality indicatiors colonoscopy artificial intelligence (ai) computer-aided detection (cade) adenoma detection rate (adr)
triple combination daas for treating hcv gt1b subjects

Conditions: Chronic Hepatitis C Infection

Summary: there is only one kind of treatment (simeprevir 150 mg + sofosbuvir 400 mg+daclatasvir 60 mg) in this study but the treatment duration may be different depending on patients' response to the antiviral therapy and whether patients have liver cirrhosis. if patients have no cirrhosis and the hcv viral load on day 2 is \<500 iu/ml, patients will receive sofosbuvir, daclatasvir and simeprevir for 3 weeks, otherwise the treatment duration is 4 weeks. if patients have cirrhosis and the hcv viral load on day 2 is \<500 iu/ml, patients will receive sofosbuvir, daclatasvir and simeprevir for 6 weeks, otherwise the treatment duration will be 8 weeks.


Eligibility criteria:
inclusion criteria: 1. hcv rna positive \>2000 iu/ml or nat poc positive 2. genotype 1b 3. cp score ≤6 exclusion criteria: 1. pregnant or nursing female or male with pregnant female partner 2. hematologic or biochemical parameters at screening outside the protocol- specified requirements 3. active or recent history (≤ 1 year) of drug or alcohol abuse 4. hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers) 5. history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate.